183 related articles for article (PubMed ID: 11600838)
1. Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men.
Taylor S; Reynolds H; Sabin CA; Drake SM; White DJ; Back DJ; Pillay D
AIDS; 2001 Oct; 15(15):2051-3. PubMed ID: 11600838
[TBL] [Abstract][Full Text] [Related]
2. Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children.
Funk MB; Notheis G; Schuster T; Elanjkal Z; von Hentig N; Stürmer M; Linde R; Dunsch D; Königs C; Wintergerst U; Kreuz W
Eur J Med Res; 2005 Dec; 10(12):503-8. PubMed ID: 16356864
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.
Else LJ; Taylor S; Back DJ; Khoo SH
Antivir Ther; 2011; 16(8):1149-67. PubMed ID: 22155899
[TBL] [Abstract][Full Text] [Related]
4. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
5. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
[TBL] [Abstract][Full Text] [Related]
6. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
[TBL] [Abstract][Full Text] [Related]
7. In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
Kollmann C; Tremblay C; Giguel F; Chou TC; Hirsch MS
Antivir Ther; 2001 Jun; 6(2):143-4. PubMed ID: 11491419
[No Abstract] [Full Text] [Related]
8. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
[TBL] [Abstract][Full Text] [Related]
9. A review of abacavir and efavirenz: new antiretroviral drugs to treat HIV-1 infection.
Wolbach J; Capoccia K
Nurse Pract; 1999 Jun; 24(6):81-2, 87-90, 92. PubMed ID: 10431297
[No Abstract] [Full Text] [Related]
10. Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy.
Craigo JK; Patterson BK; Paranjpe S; Kulka K; Ding M; Mellors J; Montelaro RC; Gupta P
AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1196-209. PubMed ID: 15588342
[TBL] [Abstract][Full Text] [Related]
11. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.
Taylor S; van Heeswijk RP; Hoetelmans RM; Workman J; Drake SM; White DJ; Pillay D
AIDS; 2000 Sep; 14(13):1979-84. PubMed ID: 10997403
[TBL] [Abstract][Full Text] [Related]
12. SSRI safe with efavirenz.
AIDS Patient Care STDS; 2000 Dec; 14(12):672-3. PubMed ID: 11187111
[No Abstract] [Full Text] [Related]
13. Efavirenz.
Adkins JC; Noble S
Drugs; 1998 Dec; 56(6):1055-64; discussion 1065-6. PubMed ID: 9878993
[TBL] [Abstract][Full Text] [Related]
14. Efavirenz plasma concentrations and efficiency.
López-Cortés LF; de Alarcón A; Viciana P
AIDS; 2001 Jun; 15(9):1192-4. PubMed ID: 11416729
[No Abstract] [Full Text] [Related]
15. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease.
Maserati R; Villani P; Seminari E; Pan A; Lo Caputo S; Regazzi MB
AIDS; 1999 May; 13(7):870-1. PubMed ID: 10357395
[No Abstract] [Full Text] [Related]
16. Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens.
Barreiro P; Oller V; Soriano V; Nuñez M; Rodríguez-Rosado R; González-Lahoz J
J Acquir Immune Defic Syndr; 2001 Apr; 26(4):391-2. PubMed ID: 11317086
[No Abstract] [Full Text] [Related]
17. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.
Langmann P; Weissbrich B; Desch S; Väth T; Schirmer D; Zilly M; Klinker H
Eur J Med Res; 2002 Jul; 7(7):309-14. PubMed ID: 12176680
[TBL] [Abstract][Full Text] [Related]
18. Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy.
Walmsley SL; Kelly DV; Tseng AL; Humar A; Harrigan PR
AIDS; 2001 Aug; 15(12):1581-4. PubMed ID: 11504994
[TBL] [Abstract][Full Text] [Related]
19. Efavirenz for HIV-1 infection in adults: an overview.
Fortin C; Joly V
Expert Rev Anti Infect Ther; 2004 Oct; 2(5):671-84. PubMed ID: 15482231
[TBL] [Abstract][Full Text] [Related]
20. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study.
Friedl AC; Ledergerber B; Flepp M; Hirschel B; Telenti A; Furrer H; Bucher HC; Bernasconi E; Weber R;
AIDS; 2001 Sep; 15(14):1793-800. PubMed ID: 11579241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
